Omalizumab outcomes for up to 6 years in pediatric patients with severe persistent allergic asthma.

Fecha de publicación: Fecha Ahead of Print:

Autores de IIS La Fe

Participantes ajenos a IIS La Fe

  • Garriga-Baraut T
  • Plaza Martín AM
  • Torres Borrego J
  • Del Mar Folqué Giménez M
  • Lozano Blasco J
  • Bosque García M
  • Moreno-Galarraga L
  • Tortajada-Girbés M
  • Rivas Juesas C
  • Penín Antón M
  • Caballero-Rabasco MA
  • Gaboli M
  • López Neyra A
  • Navarro Morón J
  • Freixa A
  • Valdesoiro Navarrete L
  • Ballester Asensio E
  • Sanz Santiago V
  • Romero García R
  • Gimeno Díaz de Atauri Á
  • Valenzuela Soria A
  • Sánchez Mateos M
  • Batlles Garrido J
  • Andrés Martín A
  • Campos Alonso E
  • Aragón Fernández C
  • Vázquez Rodríguez E
  • Martínez Pardo L
  • Del Río Camacho G

Grupos

Abstract

Various studies have assessed omalizumab outcomes in the clinical practice setting but follow-up and/or number of patients included were limited. We aim to describe the long-term outcomes of pediatric patients with severe persistent allergic asthma receiving omalizumab in the largest real-life cohort reported to date.

Datos de la publicación

ISSN/ISSNe:
0905-6157, 1399-3038

PEDIATRIC ALLERGY AND IMMUNOLOGY  WILEY-BLACKWELL PUBLISHING, INC

Tipo:
Article
Páginas:
980-991
PubMed:
33619748
Factor de Impacto:
1,264 SCImago
Cuartil:
Q1 SCImago

Citas Recibidas en Web of Science: 32

Documentos

  • No hay documentos

Métricas

Filiaciones mostrar / ocultar

Keywords

  • Children, adolescents, anti-asthmatic agents, humanized monoclonal antibodies, observational study, omalizumab, real-life, severe asthma

Cita

Compartir